0041山師さん@トレード中 (ニククエ a20f-53i4 [123.216.31.58])2018/07/29(日) 13:43:50.95ID:S9IWFi0L0NIKU 保守 0042山師さん@トレード中 (ニククエ MM0f-eOoN [110.165.202.129])2018/07/29(日) 15:13:42.64ID:JS1b8sq6MNIKU このクソスレ必要ですか? 0043山師さん@トレード中 (ニククエWW b711-Pd1V [60.126.17.145 [上級国民]])2018/07/29(日) 15:33:27.72ID:HRUWsRf40NIKU o(^o^)o 0044山師さん@トレード中 (ニククエ Sd62-8trp [1.75.247.76])2018/07/29(日) 16:14:38.86ID:dWtk5LgqdNIKU もうここにスレ建てないでください 情報共有の場なら他にもあります 0045山師さん@トレード中 (ニククエ 4b8e-9nzk [202.124.52.145 [上級国民]])2018/07/29(日) 18:00:39.56ID:W3QsNmv90NIKU MiNA Therapeutics: ・・・ ※SOSEI:MiNA社に対する3,500万英ポンド投資(25.6%株式取得)および同社買収オプション権(全株式取得)を含む投資契約の締結:プラットフォーム技術の補完、戦略M&Aによる成長戦略。(2017/5/3) ・OUTREACHの結果による段階的な条件付対価体系。"OUTREACHフェーズ1/2a臨床試験からの重要臨床データは、2018年中に明らかになる見込です。" ※SOSEI決算説明会:MiNA社買収のオプション権を含む投資契約:そーせいグループのパイプライン開発の加速並びに拡大、目覚ましく拡張した技術プラットフォームを創出。新たな基盤技術獲得の可能性。(2017/5/12) :直近12-18 ヶ月の見通し:MiNA:パイプラインがPh2b/3臨床試験へと進展。(MTL-CEBPA 進行性肝がん(HCC)を適用としたPh1/2aの臨床データ読み出し:Ph2b/3へと開発が進捗。) ・その他の適用でMTL-CEBPAのPh1/2a臨床試験が開始。・その他のsaRNAターゲットにおける前臨床試験が開始。 ※ClinicalTrials: Phase 1/2a, First-in-Human Safety and Tolerability Study of MTL-CEBPA in Patients With Advanced Liver Cancer (OUTREACH): "Add, 2a Protocol". (2017/5/24update) ※ClinicalTrials: First-in-Human Safety and Tolerability Study of MTL-CEBPA in Patients With Advanced Liver Cancer: Primary Completion: 2017-09→"2018-09" Study Completion: 2017-12→"2018-12". (2017/6/14update) ※SOSEI (English):Presentation Material as of July 2017: "For Further Growth.", "Potential to have Two Discovery Engines: StaR & SBDD (Heptares), saRNA Therapeutics (MiNA)". (2017/7/5) ・saRNA Technology offers potential for new discovery engine: RNAa represents a platform technology that can rapidly generate a portfolio of programs: "12 months from target selection to development candidate". ※MiNA Therapeutics: Announces Publication of Pre-Clinical Data Supporting On-Target Mechanism of Action of Clinical Candidate MTL-CEBPA. (2017/9/6) ※MiNA Therapeutics: MiNA Research Team at OTS2017. "MTL-CEBPA has Efficacy in a Broad Range of Liver Disease Models and Encouraging Early Clinical Data in a Phase 1 Trial in HCC." (2017/9/22 Presented) ※MiNA Therapeutics: MiNA Research Featured as a HOT PAPER by OTS. Best Ones to Highlight Them! "Novel Therapeutic in Clinical Trials for Liver Cancer." (2017/10/23) 0046山師さん@トレード中 (ニククエ 4b8e-9nzk [202.124.52.145 [上級国民]])2018/07/29(日) 18:01:01.19ID:W3QsNmv90NIKU ※MiNA Therapeutics: Innovate UK Awards Grant to "MiNA" and "LGC LINK": Exciting New Area of Research in Collaboration. Grant of up to Approximately £400,000 will Support a Two-Year. (2017/11/2) ※MiNA Therapeutics: Boehringer Ingelheim and MiNA Therapeutics to Develop Novel Treatment Approaches for Fibrotic Liver Diseases. (2017/11/8) ・"This collaboration is a recognition of our platform and expertise in liver-based diseases as well as validation from an established pharmaceutical leader in what has been an exciting year for the company." ・"This new collaboration is another sign of our ongoing commitment to patients with cardio-metabolic diseases, including NASH." ・"It will combine MiNA’s pioneering work with saRNAs with our expertise in biopharmaceutical research and development." ※SOSEI:MiNA社、Boehringer Ingelheim社と線維性肝疾患の新治療法開発でライセンス契約締結。契約一時金や研究資金に加え、最大総額307百万ユーロのマイルストンを受領予定。(2017/11/8) ・さらに、MiNA社は、共同研究開発により開発された医薬品全ての販売高に応じて二桁パーセントのロイヤルティを受領する権利を有します。 ※SOSEI第2四半期決算説明資料:経営資源の最適な配分を実現する戦略的フレームワーク:価値最大化の最適な実現に向けて。ビジネスハイライト:オペレーション及び経営戦略上の重要な進捗を複数実現。(2017/11/9) ・MiNA社への戦略的な投資により、将来性の高いRNA治療薬領域に参入:Boehringer Ingelheim社との提携は、MiNA社が有するsaRNA技術の高い可能性を立証。 ・MiNA:提携契約・ライセンス契約をBI社と締結。MiNA社は契約一時金や研究開発資金並びに、マイルストンで最大307百万ユーロを受領する予定。(New) ※米国特許出願(MiNA):Albumin Production and Cell Proliferation. (2017/11/9公開) ※MiNA Therapeutics: "Development and Mechanism of Small Activating RNA Targeting CEBPA, a Novel Therapeutic in Clinical Trials for Liver Cancer" (2017/12/1up) 0047山師さん@トレード中 (ニククエ 4b8e-9nzk [202.124.52.145 [上級国民]])2018/07/29(日) 18:01:43.39ID:W3QsNmv90NIKU ※SOSEI (English) Presentation Material: (J.P. Morgan Healthcare Conference: 1/8): Strategic investment in saRNA therapeutics with lead candidate in Phase 1/2a for liver cancer, an orphan indication. (1/16up) ・We are excited about the potential of saRNA therapeutics. MiNA’s recent deal with Boehringer Ingelheim further supports MiNA/saRNA’s potential. ※米国特許(MiNA):Methods of Inducing Insulin Production. (2/6公開) ※RNA Therapeutics Conference, London: "Utilising Small Activating RNA (saRNA) for Therapeutic Opportunities": Nagy Habib, Chairman and Co-Founder, MiNA Therapeutics. Attend: Heptares. (2/21 Presented) ※欧州特許出願(MiNA):Sarna Compositions and Methods of Use. (2/28公開) ※欧州特許出願(MiNA):C/EBP Alpha Sarna Compositions and Methods of Use. (2/28公開) ※MiNA Therapeutics: Read about Our CEO Robert Habib in an Interview with OTS (Oligonucleotide Therapeutics Society). (3/2) ※Oncogene: "Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer" (3/7) ※MiNA Therapeutics: Small Step Up to 1st Floor at the Translation & Innovation Hub (Imperial College London White City Campus). (3/8) ※MiNA Therapeutics: Announces Publication of Pre-Clinical Data Supporting Therapeutic Potential of Clinical Candidate MTL-CEBPA in Liver Cancer and Liver Disease. (3/9) ※米国特許(MiNA):Albumin production and cell proliferation. (4/17公開) ※米国特許出願(MiNA): Methods of Inducing Insulin Production. (4/26公開) 0048山師さん@トレード中 (ニククエ 4b8e-9nzk [202.124.52.145 [上級国民]])2018/07/29(日) 18:02:22.96ID:W3QsNmv90NIKU ※SOSEI:2018年3月期決算説明会:「戦略プランを着実に実行し2017年度は著しい進捗を達成」。MiNA Therapeuticsにおける開発は順調に進行。(5/10) ・MTL-CEPBAの第1/2a相臨床試験の進捗は良好。MiNAの追加株式取得のオプション行使の判断のタイミングは2018年下半期。 ※TIDES: Oligonucleotide and Peptide Therapeutics 2018: "RNA Activation in NASH, Liver Failure and Hepatocellular Carcinoma": Nagy Habib, MiNA Therapeutics. (5/10 Presented) ※MiNA Therapeutics to Present Initial Results from First-in-Human MTL-CEBPA Study at the 2018 ASCO Annual Meeting. MiNA will Announce the Results Through a Press Release Following the Presentation. (5/16) ※ASGCT: "Short Activating RNAs. MTL-CEBPa has a Broad Range of Liver Disease Models and Encouraging Early Clinical Data in a Phase 1 Trial in HCC": Nagy Habib, MiNA Therapeutics. (5/18 Presented) ※SOSEI Presentation: "Sosei Group Corporation, UBS Global Healthcare Conference": Global operations and aspirations - aiming to build Japan’s first global biotech champion: Drive Global Growth Strategy. (5/21Presented, 5/22up) ・Strategic investment in saRNA technology, Exclusive option to move from 25.6% to 100% ownership at pre-determined economics: MiNA Therapeutics. ・Strategic investment in saRNA therapeutics with lead candidate in Phase 1/2a for liver cancer, an orphan indication: MiNA Therapeutics. ※ASCO 2018: "Preliminary results of a first-in-human, first-in-class phase I study of MTL-CEBPA, a small activating RNA targeting the transcription factor C/EBP-α in patients with advanced liver cancer": MiNA Therapeutics. (6/4 Presented) ※MiNA Therapeutics Presents Initial Results from First-in-Human MTL-CEBPA Study in Advanced Liver Cancer Patients. First look at saRNA therapeutics in patients - Initial results from Phase 1 study of MTL-CEBPA in patients with liver cancer presented. (6/4) ※Robert Habib: A very promising start for saRNA medicines in patients! Looking forward to future development of MTL-CEBPA drug candidate. Dr Sarker from GSTTnhs presenting initial clinical results of MTL-CEBPA today at ASCO 2018. (6/4) ※SOSEI:MiNA Therapeuticsが進行肝がん患者を対象とする MTL-CEBPA の初めてのヒト試験の初期結果を発表:正常肝機能および肝機能障害のある患者において良好な忍容性がみられた。血液検体の解析によりRNA活性機序を実証。薬効標的への作用を確認。(6/5) 0049山師さん@トレード中 (ニククエ 4b8e-9nzk [202.124.52.145 [上級国民]])2018/07/29(日) 18:03:08.70ID:W3QsNmv90NIKU ※Heptares_HP: Download Corporate Presentation: "2018.06.08 Corporate Presentation (Sosei Group Corporation Corporate Presentation June 2018)". (6/8up) ※Robert Habib: "Benchling" growing (Today, Announce our Series B funding.). We are happy customers. MiNA Therapeutics. (6/15) ※EHA: "MTL-CEBPA, a Small Activating RNA for Intravenous Administration to Enhance C/EBPΑ Expression in Patients with Liver Cancer Shows Potential Use in Neutropenia": Choon Ping Tan, MiNA Therapeutics. (6/16 Presented) ※City of Hope: Researchers Use Nanoparticles to Test Treatment for Liver Disease. Promising Results: In the study, saRNAs aimed at upregulating CEBPA were encapsulated in SMARTICLES nanoparticles to deliver a treatment called MTL-CEBPA in multiple liver disease models. (6/25) ・In a model of advanced liver cirrhosis, MTL-CEBPA significantly reversed liver fibrosis and liver dysfunction, enhancing survival. ・MTL-CEBPA also reversed the buildup of fat in a model of nonalcoholic fatty liver disease, improved liver function and reduced tumor size in a model of primary liver cancer. ・According to Rossi, research into the precise mechanism of action in CEBPA is currently under investigation in his laboratory. ・In addition to Rossi and Habib, additional researchers from Imperial College London, Queen Mary University of London, National Taiwan University, Norwegian University of Science and Technology, the Biomedical Research Foundation of the Academy of Athens, ・MiNA Therapeutics and BioTD Strategies LLC collaborated on the work. ※MiNA Therapeutics_HP: Renewal. "Development Programs" update. (7/3up) ※MiNA Therapeutics: Exited to launch our new website. Head minatx.com to learn more about small activating RNA medicines. (7/6) ※日本核酸医薬学会第4回年会 博多:Oligonucleotide Therapeutics Societyシンポジウム:OTS-1:"MTL-CEBPA has efficacy in a broad range of liver disease models and encouraging early clinical data in a Phase 1 trial in HCC": MiNA Therapeutics. (7/11 Presented) ※MiNA Therapeutics: MiNA research lab very happy with our new western blot machine. Cool technology that gives us better results, faster. ProteinSimple. (7/13) ※米国特許出願(MiNA):"Albumin Production and Cell Proliferation". (7/19公開) 0050山師さん@トレード中 (ニククエ 4b8e-9nzk [202.124.52.145 [上級国民]])2018/07/29(日) 18:16:10.36ID:W3QsNmv90NIKU ・・・ 0051山師さん@トレード中 (ニククエ 4b8e-9nzk [202.124.52.145 [上級国民]])2018/07/29(日) 18:19:34.95ID:W3QsNmv90NIKU ※Imperial College London, Imperial Innovations: "Incubator 18 Month Review and MiNA Therapeutics Graduation" (7/31 18:00-20:30) 0052山師さん@トレード中 (ニククエ 4b8e-9nzk [202.124.52.145 [上級国民]])2018/07/29(日) 18:30:32.35ID:W3QsNmv90NIKU ・・・ ※ILCA Annual Conference, London, UK: MiNA Therapeutics. (9/14-16) ※OTS(Oligonucleotide Therapeutics Society) Annual Meeting 2018, Seattle, USA: MiNA Therapeutics. (9/30-10/3) ※BIO-Europe, Copenhagen, Denmark: MiNA Therapeutics. (11/5-7) ※AASLD Liver Meeting 2018, San Francisco, USA: MiNA Therapeutics. (11/9-13) ※Jefferies London Healthcare Conference, London, UK: MiNA Therapeutics. (11/14-15) ・・・ 0053山師さん@トレード中2018/07/29(日) 20:09:16.48ID:O9sLBFl7 週末はバカルサー共はなんかバイトでもしてるのかね?w
15年01-03月 売上2720 営利1027 最終254 15年04-06月 売上575 営利-1054 最終-955 15年07-09月 売上1965 営利301 最終-173 15年10-12月 売上5201 営利4202 最終3421 16年01-03月 売上410 営利-2374 最終-3725 16年04-06月 売上15082 営利12955 最終11150 16年07-09月 売上757 営利-732 最終-434 16年10-12月 売上1279 営利410 最終56 17年01-03月 売上1783 営利-244 最終-975 17年04-06月 売上2784 営利731 最終292 17年07-09月 売上2530 営利713 最終-970 17年10-12月 売上963 営利-1538 最終-1035 18年01-03月 売上678 営利-2197 最終-941 18年04-06月 ? 0130山師さん@トレード中 (ワッチョイWW bf11-FLDO [126.11.188.91])2018/07/31(火) 03:18:07.37ID:y+OtRpNO0>>127 じげんとか一部発表前後もモルスタに普通に売られてたよ 0131山師さん@トレード中 (ワッチョイWW bf11-FLDO [126.11.188.91])2018/07/31(火) 03:43:48.12ID:y+OtRpNO0 次のa又はbのいずれかに適合すること a. 最近2年間の利益の額の総額が5億円以上であること b. 時価総額が500億円以上(最近1 年間における売上高が100 億円未満である場合を除く) 0132山師さん@トレード中 (ワッチョイ 4b8e-9nzk [202.124.52.145 [上級国民]])2018/07/31(火) 06:00:25.14ID:tUYSsrXc0 次なる飛躍へ。着実な進捗と共に更なる成長の黎明期にて振るい育ちゆく相場。控える材料と共に水準訂正。笑。 成長期。予定されていた業績の急成長と共に更なる成長戦略が進展。順調なR&D・PL等の拡充・拡大の加速。笑。 Heptares is based the New Research Facility (Steinmetz Building) of Granta Park (Cambridge) from August 2018. ・・・ ※Trial Profile: A randomized, double-blind, placebo controlled, dose ranging study to assess the safety, tolerability, and efficacy of HTL0018318 in patients with dementia with Lewy bodies: JapicCTI-183989(6/6新規作成):予定試験期間:2018/6/1〜2020/7/31、被験者募集状況:募集前、日本. (6/28update) ※医薬品原料国際展in-Pharma Japan (JITSUBO出展6/27~6/29)・技術セミナーも開催「新規ペプチド原薬製造法の開発」:液相、固相合成法に続く第3世代のペプチド合成技術Molecular Hivingの創薬研究および原薬製造への適用と、更なる進化への取り組み紹介。(6/29) ※ClinicalTrials(NCT03381274): Phase 1b/2, Oleclumab(MEDI9447) EGFRm NSCLC Novel Combination Study. (MEDI9447 with Osimertinib or AZD4635, AZD4635 with MEDI9447). Research Site Status Change: Korea Seoul (03080): "Recruiting". (6/29update) ※大阪大学大学院医学系研究科:「認知症プレシジョン医療開発学」寄附講座開講(寄附講座教授:森原剛史)。発症メカニズムの分子レベルの解明とバイオマーカーの開発、認知症サブグループに対する効率的な治療法開発を目指す。臨床と分子生物学の両分野に強い阪大精神科の強みを活かす。(7/1) ※日本国特許庁(公開商標公報):【商標】MATILDA 【商品及び役務】バイオ技術・薬剤・科学に関する試験・研究・開発・指導・助言並びにこれらに関する情報の提供及びコンサルティング等【出願人】ヘプタレス【出願番号】商願2018-79942【出願日】2018/6/18【公開日】2018/7/3。(7/3公開) ※World Congress of Basic and Clinical Pharmacology, Kyoto: "PLX-R18- Placenta-derived Mesenchymal-like Stromal Cells are efficacious in reducing lethality in Gastrointestinal Acute Radiation Syndrome (GI-ARS) Mouse Model": Yoshiyuki Soeda, Fukushima Medical University. (7/3 Presented) ※MiNA Therapeutics_HP: Renewal. "Development Programs" update. (7/3up) ※MiNA Therapeutics: Exited to launch our new website. Head minatx.com to learn more about small activating RNA medicines. (7/6) ※Pluristem: Signs Collaboration Agreement With Thermo Fisher Scientific: Advance fundamental knowledge of cell therapy industrialization and to improve quality control of the end-to-end supply chain. "A potential to advance the industry significantly". (7/9) ※ClinicalTrials(NCT02740985): A Phase 1 (Ph1b Expansion Cohorts) Clinical Study of AZD4635 and Durvalumab in Patients With Advanced Solid Malignancies. Enrollment: 156→"206”(Change), Secondary Outcome Measures (Change), Eligibility (Change), Study Research Site (Add). (7/16update) ※ClinicalTrials(NCT02571777): Phase 3, Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients with Asthma. Study Locations: (Research Site update, Research Site Status update). (7/16update) ※Novartis Q2 2018 Results: Continued Strong Growth of Ultibro (USD 116 million, +11% cc). QVM149 Asthma: First planned submissions: "2019", Expected Launches: "2020". News update: "QVM149 IRIDIUM study enrollment completed end of April". (7/18) ※SOSEI:「シーブリおよびウルティブロ」の2018年第2四半期(4月〜6月)の業績。ウルティブロは当四半期において、FLAME, CLAIM studyの良好な結果、2018年版GOLDレポート、さらにSUNSET studyに後押しされ、売上は二桁の伸び。シーブリの売上は、ほぼ横ばい。(7/18) ※米国特許出願(MiNA):"Albumin Production and Cell Proliferation". (7/19公開) 0133山師さん@トレード中 (ワッチョイ 4b8e-9nzk [202.124.52.145 [上級国民]])2018/07/31(火) 06:01:04.69ID:tUYSsrXc0 ※JapicCTI-183989:レビー小体型認知症患者を対象としたHTL0018318の安全性、忍容性及び有効性を評価する無作為化二重盲検プラセボ対照用量範囲探索試験 (予定試験期間:2018/6/1〜2020/7/31、目標症例数172、被験者募集状況:募集前→参加者募集中、日本)。(7/19改訂) ※ClinicalTrials(NCT03592862: HTL0018318-203): Phase 2, A Study to Assess Safety, Tolerability, and Efficacy of HTL0018318 in Patients With Dementia With Lewy Bodies (DLB). Study Start: "August 2018". Primary Completion: "July 2020", Study Completion: "January 2021". (7/19up, "New Trial Record".) ※ClinicalTrials(NCT03456349: HTL0018318-202): Phase 1b, Multi-center Study to Determine the Safety and Tolerability of HTL0018318 in Subjects With Alzheimer's Disease Receiving Standard-of-care. Actual Study Completion: "2018/7/16" (7/20update, "Completed".) ※Pluristem: Company Presentation July 2018: PLX-PAD CLI: Single pivotal study (Japan PMDA). Collaboration with Fukushima Medical University: Collaboration with Fukushima Medical University: Suggesting PLX-R18 potential as a multi-organ therapy for radiation exposure. (7/23update) ※トレーダーズ・ウェブ:著名投資家が株買い増し。23日公表の大量保有報告書で、同社の筆頭株主でもある五味大輔氏が19日時点で保有株比率を従来の6.13%から7.16%へと引き上げたことが判明し、投資妙味があるとの期待から買いが集中。(7/24) ※米国特許(Heptares):"Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists". (7/24公開) ※米国特許(Heptares):"Muscarinic receptor agonists". (7/24公開) ※ClinicalTrials(NCT03100825): Phase 3, A Long-term Safety Study of QVM149 in Japanese Patients With Asthma. Study Start: "2017/4/13 [Actual]", Primary Completion: 2018/9/18, Study Completion: "2019/4/8, Study Enrollment: "94 participants [Actual]". (7/24update) ※メルトレ:そーせいグループHTL18318の国内フェーズ2試験が8月に開始。「HTL18318 セールスピーク800億円予想」。国内大手証券バイオセクターアナリストは、「重要な進捗でプラスな印象」とコメント。今回の試験期間は2018年8月〜2021年1月の予定、患者数172人、有効性の観察期間は12週間。(7/25) ※Heptares: "All set for our study of HTL0018318 in Patients with Dementia with Lewy Bodies (DLB)". (7/25) ※AstraZeneca H1 and Q2 2018 Results: Clinical Trials Appendix Q2 2018 results update: Movement since Q1 2018 update: New to Phase I (Additional indications): "oleclumab+AZD4635 (CD73 mAb + A2aR inhibitor EGFRm NSCLC)". (7/26) ※Pluristem: Granted Key Patent in Japan for Treatment of GI Following Acute Radiation Exposure. Recent data from Fukushima University shows PLX-R18 cells significantly increased survival and enhanced the recovery of the GI tract after radiation exposure. (7/26) ※日本プロセス化学会2018サマーシンポジウム:「疎水性タグを用いたIcatibant Acetateの合成」久保大輔(JITSUBO) (7/27 14:40-16:20) ※大日本住友製薬2019年3月期 第1四半期決算。北米COPD治療剤(導入3製品):2018年度1Q実績:2億円(2017年度1Q実績1億円)、増減額:0億円、増減率29.5%(北米現地通貨ベース増減率31.9%)、2018年度2Q累計予想:10億円、進捗率:15.3%、2018年度通期予想:29億円。(7/27) 0134山師さん@トレード中 (ワッチョイ 4b8e-9nzk [202.124.52.145 [上級国民]])2018/07/31(火) 06:03:13.48ID:tUYSsrXc0 ※大日本住友製薬2019年3月期 第1四半期決算カンファレンスコール音声配信:[Q&A2:北米COPD導入3品目について]. (7/30up)
※Avacta Group: Proposed Placing and Subscription to raise £11.4m. (7/30) Current Trading and Outlook ・With regards to Affimer research and diagnostics reagents, the focus is on licensing opportunities for reagents in non-therapeutic markets: progress has been made with multiple third-party technology evaluations and Avacta is expecting further licensing deals in 2018. ・In addition, there has been strong growth in public validations of Affimer technology by third parties. ・This includes a record period for publication of third party peer reviewed scientific papers using Affimers as well as public support by likes of Covance and Heptares. 0135山師さん@トレード中 (ワッチョイ 4b8e-9nzk [202.124.52.145 [上級国民]])2018/07/31(火) 06:03:40.93ID:tUYSsrXc0 ※ClinicalTrials(NCT03381274): Phase 1b/2, Oleclumab(MEDI9447) EGFRm NSCLC Novel Combination Study. (MEDI9447 with Osimertinib or AZD4635, AZD4635 with MEDI9447). (7/30update) Study Status Change: ・Primary Completion: 2022/1/10→"2021/12/14[Anticipated]" ・Study Completion: 2022/1/10→"2021/12/14[Anticipated]" Study Research Site Status Change: ・La Jolla, California, United States: Not yet Recruiting→"Recruiting" ・Baltimore, Maryland, United States: Not yet Recruiting→"Recruiting"